^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Gastroesophageal Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Excerpt:
    Keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)

    Excerpt:
    Willing to provide tissue for PD-L1 biomarker analysis from newly-obtained and/or archival tissue...
    Trial ID:
    KEYNOTE-059
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10

    Published date:
    02/14/2021
    Excerpt:
    ...pembrolizumab monotherapy given as first-line (KEYNOTE-062), second-line (KEYNOTE061), and third-line and later (KEYNOTE-059) therapy showed a clinically meaningful median and long-term survival benefit in patients with CPS ≥ 10 gastric or GEJ tumors and more durable responses compared with chemotherapy.
    DOI:
    10.1158/1078-0432
    Trial ID:
    KEYNOTE-059